You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家醫保局:納入醫保藥品以五年內獲批新藥爲主
據《北京日報》引述國家醫保局表示,內地近年加快醫保談判節奏,新藥從上市到納入醫保目錄的等待時間從平均五年縮短至不到兩年,部分新藥上市僅半年就被納入醫保目錄。被納入醫保目錄的藥品以五年內獲批新藥爲主。 此外,內地還建立健全談判藥品「雙通道」供應保障機制,通過醫院和零售藥店兩個渠道向患者供應談判藥品,並實行相同的報銷政策,過去兩年內新增15.5萬家定點零售藥店供應談判藥品,極大解決藥品「進得了醫保、進不了醫院」的瓶頸問題。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account